TABLE 2.
The effects of a KD associated with RT in mouse cancer models1
| Authors, year (ref) | Type of cancer model | Therapeutic protocol | KD, % of lipids/carbohydrates/proteins | RT administration | Oncological effects |
|---|---|---|---|---|---|
| Abdelwahab et al., 2012 (75) | Glioma (GL261-luc2 cells); intracranial implantation in albino mice | KD + RT vs SD + RT | 72/3/15 | Whole-brain irradiation: 2 × 4 Gy | RTV |
| Allen et al., 2013 (76) | Lung cancer (NCI-H292 and A549 cells) | KD ± RT ± CT (carboplatin) | 90/1.6/8.4 | 34 times 1.8 Gy, 6 times 2 Gy; CON group: 2 times 6 Gy | RTV and ISKD alone; no effect |
| Zahra et al., 2017 (77) | Pancreas cancer (Mia-Paca-2 cells) | KD + RT | 69/2.8/14.3 | 12 Gy: 6 × 2 Gy | RTV and IS |
1CON group, control group; CT, chemotherapy; IS, increasing survival; KD, ketogenic diet; ref, reference; RT, radiotherapy (conventionally fractionated, 1.8–2 Gy; or hypofractionated (6 Gy) radiation as well as conventionally fractionated radiation); RTV, regression of tumor volume; SD, standard diet.